TY - JOUR
T1 - Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes
AU - DeZern, Amy E.
AU - Binder, Gary
AU - Rizvi, Syed
AU - Corvino, Frank A.
AU - Arikian, Steven R.
AU - Surinach, Andy
AU - Lee, Jianyi
AU - Smith, B. Douglas
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/11/2
Y1 - 2017/11/2
N2 - Transfusion dependence (TD) among myelodysplastic syndromes (MDS) patients negatively impacts survival and health-related quality of life. We evaluated cost patterns of MDS care during TD and transfusion independence (TI). MDS patients were identified from a US claims database (2008–2013). TD was defined as ≥2 consecutive 8-week periods with ≥1 claim during each, and no interim 56-day period without transfusion; TI as 8 subsequent transfusion-free weeks; and transfusion frequency as the mean interval between transfusions during the TD period. 13,741 patients were included; 19% were TD and 70% had a mean interval between transfusions of ≤28 days. During a 2-year period, TD patients incurred a mean total cost of $17,815/patient-month; 53% higher for those with ≤28 days ($19,498) vs. >28 days ($12,717) between transfusions. Among patients who achieved TI, mean total cost was $7874/patient-month. For TD-MDS patients, cost increases are proportional to transfusion frequency and achieving TI yields economic benefits.
AB - Transfusion dependence (TD) among myelodysplastic syndromes (MDS) patients negatively impacts survival and health-related quality of life. We evaluated cost patterns of MDS care during TD and transfusion independence (TI). MDS patients were identified from a US claims database (2008–2013). TD was defined as ≥2 consecutive 8-week periods with ≥1 claim during each, and no interim 56-day period without transfusion; TI as 8 subsequent transfusion-free weeks; and transfusion frequency as the mean interval between transfusions during the TD period. 13,741 patients were included; 19% were TD and 70% had a mean interval between transfusions of ≤28 days. During a 2-year period, TD patients incurred a mean total cost of $17,815/patient-month; 53% higher for those with ≤28 days ($19,498) vs. >28 days ($12,717) between transfusions. Among patients who achieved TI, mean total cost was $7874/patient-month. For TD-MDS patients, cost increases are proportional to transfusion frequency and achieving TI yields economic benefits.
KW - Myelodysplastic syndromes
KW - cost
KW - health-related quality of life
KW - transfusion dependence
KW - transfusion independence
UR - http://www.scopus.com/inward/record.url?scp=85019102572&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019102572&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1312372
DO - 10.1080/10428194.2017.1312372
M3 - Article
C2 - 28482722
AN - SCOPUS:85019102572
SN - 1042-8194
VL - 58
SP - 2649
EP - 2656
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -